Source: FinanzNachrichten

Nicox: NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025C...

Read full article »
Nicox's Competitors | Nicox's News | Nicox's Financials
Stay up-to-date with the latest news on Nicox
Annual Revenue
$5.0-25M
Employees
1-25
Gavin Spencer's photo - CEO of Nicox

CEO

Gavin Spencer

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Nicox